{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:50:39Z","timestamp":1787068239648,"version":"build-2736575974"},"reference-count":17,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>Interstitial pneumonitis as an adverse effect of mesalamine therapy is a rare but potentially serious complication. Patients typically have a mild disease course with no documented cases of respiratory failure in published literature. Given its variable latent period and non-specific signs and symptoms, it may be difficult to diagnose. We present the case of a 65-year-old man who presented with symptoms of fever, shortness of breath and a non-productive cough, 2\u2005weeks after initiation of therapy with mesalamine. His hospital course was complicated by acute respiratory failure requiring intubation and mechanical ventilation. Radiographic studies revealed bilateral lower lobe infiltrates and bronchosopy with bronchoalveolar lavage and transbronchial biopsy were consistent with a diagnosis of drug-induced interstitial pneumonitis. The aim of this paper is to highlight the importance of considering a diagnosis of mesalamine-induced lung injury in patients presenting with respiratory symptoms while on mesalamine therapy and to review relevant literature.<\/jats:p>","DOI":"10.1136\/bcr-2013-009834","type":"journal-article","created":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T10:45:28Z","timestamp":1376995528000},"page":"bcr2013009834","source":"Crossref","is-referenced-by-count":11,"title":["Acute respiratory failure secondary to mesalamine-induced interstitial pneumonitis"],"prefix":"10.1136","volume":"2013","author":[{"given":"Albin","family":"Abraham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Karakurum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2013,8,20]]},"reference":[{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.1","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clincal epidemiology of inflammatory bowel disease: incidence, prevalence and enviornmental influences","volume":"2013","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ibd.20029","article-title":"Update on the incidence and prevalence of Chron's disease and ulcerative colitis in Olmstead County, Minnesota 1940\u20132000","volume":"2013","author":"Loftus","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.3","first-page":"3204","article-title":"Current treatment of ulcerative colitis","volume":"2013","author":"Meier","year":"2011","journal-title":"World J Gastroenterol"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.4","first-page":"41","article-title":"Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX mesalamine","volume":"2013","author":"Nanda","year":"2012","journal-title":"Clin Pharmacol"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00054725-200405000-00005","article-title":"Autoimmune disorders and extraintestinal manifestations in first degree familial and sporadic inflammatory bowel disease: a case- control study","volume":"2013","author":"Ricart","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.crohns.2007.08.009","article-title":"Pulmonary abnormalities in inflammatory bowel disease","volume":"2013","author":"Schleiermacher","year":"2007","journal-title":"J Crohns Colitis"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.7","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/00054725-200309000-00004","article-title":"Mesalamine related lung disease: clinical, radiographic and pathologic manifestations","volume":"2013","author":"Foster","year":"2003","journal-title":"Inflamm Bowel Dis"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3109\/00365529009091915","article-title":"Mesalamine: a global safety evaluation","volume":"2013","author":"Brimblecombe","year":"1990","journal-title":"Scand J Gastroenterol Suppl"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.9","first-page":"389","article-title":"Can a drug induced pulmonary hypersensitivity reaction be dose dependent? A case with mesalamine","volume":"2013","author":"Sossai","year":"2001","journal-title":"Mt Sinai J Med"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/14740338.6.2.99","article-title":"The risks and benefits of meslamine as a treatment for ulcerative colitis","volume":"2013","author":"Moss","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/gut.51.4.536","article-title":"Sulphasalazine and mesalazine: serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines","volume":"2013","author":"Ransford","year":"2002","journal-title":"Gut"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.12","doi-asserted-by":"crossref","unstructured":"Cilloniz R Chesrown S Gonzalez-Peralta R . Asymptomatic presentation of mesalamine induced lung injury in an adolescent with Crohn's disease. BMJ Case Rep. Published Online: 20 Mar 2000. doi:10.1136\/bcr.09.2008.0908","DOI":"10.1136\/bcr.09.2008.0908"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.13","first-page":"265","article-title":"Mesalamine lung toxicity","volume":"2013","author":"Jain","year":"2010","journal-title":"Conn Med"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1465-9921-13-39","article-title":"Drug induced interstitial lung disease: mechanisms and best diagnostic approaches","volume":"2013","author":"Matsuno","year":"2012","journal-title":"Respir Res"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.15","first-page":"1039","article-title":"Mesalamine induced lung toxicity","volume":"2013","author":"Bitton","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.16","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1378\/chest.101.5.1469","article-title":"Lung disease associated with orally administered mesalamine for ulcerative colitis","volume":"2013","author":"Reinoso","year":"1992","journal-title":"Chest"},{"key":"2025042709050203000_2013.aug20_1.bcr2013009834.17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00005792-199372030-00003","article-title":"The lung in inflammatory bowel disease","volume":"2013","author":"Camus","year":"1993","journal-title":"Medicine"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2013-009834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T12:05:13Z","timestamp":1745755513000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2013-009834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,20]]},"references-count":17,"alternative-id":["10.1136\/bcr-2013-009834"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2013-009834","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,20]]}}}